Nevirapine (Viramune): Research
- Nevirapine Patient Assistance Program: Model for Better Administration? (November 22, 2002)
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Ethiopia Ready to Start Nevirapine Trials for AIDS Treatment (November 20, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Nevirapine and Vivid Dreams (September 12, 2002)
From Canadian AIDS Treatment Information Exchange
- Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Promoting Prevention of Mother-to-Child Transmission of HIV Through the Viramune Donation Programme: A Model of Public-Private Partnership (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- WHO and UNAIDS Continue to Support Use of Nevirapine for Prevention of Mother-to-Child HIV Transmission (March 22, 2002)
From UNAIDS
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Effect of Nevirapine (NVP) for Perinatal HIV Prevention Appears Greatest Among Women With Most Advanced Disease: Subgroup Analyses of HIVNET 012 (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Nevirapine and Protease Inhibitor-Based Regimens in a Directly Observed Therapy (DOT) Program for Intravenous Drug Users (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012) (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Nevirapine Notes (November 2001)
In HIV Treatment ALERTS!, from The Center for AIDS
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Rise in HDL Cholesterol Associated With Nevirapine Containing Antiretroviral Therapy in HIV-1 Infected Patients Is Sustained Over 48 Weeks of Treatment (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Retrospective Review of Nevirapine-Induced Hepatotoxicity in HIV/HCV Co-Infected Patients in a Community Health Center (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Impact of HIV-1 Subtype on Women Receiving Single Dose Nevirapine Prophylaxis to Prevent HIV-1 Vertical Transmission (October 2, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Study Finds Women More Likely to Get Rash With Nevirapine Than Men (August 16, 2001)
From Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Nevirapine-Containing Antiretroviral Therapy in HIV-1-Infected Patients Results in an Anti-Atherogenic Lipid Profile (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
